For journalists, podcasters, and newsletter writers
Designing Longevity is an independent editorial operation that publishes verifiable, primary-source-linked analysis of telehealth providers in GLP-1, hormone replacement, and DTC lab testing. If you are covering a story in this space, the following resources may be useful.
What we have that may be useful
2025-2026 Telehealth Provider Regulatory Timeline
Dated regulatory chronology covering FDA actions, manufacturer litigation, and Washington's March 2025 Limited Stop Service against Aequita Pharmacy. Each event links to its cited source.
View the timelineVetted provider directory (13 providers)
Independently scored on a public six-dimension rubric: licensure, accreditation, transparency, product quality, pricing, customer service. Every score has a one-line rationale and source URLs for the verifications behind it. Cohort spans GLP-1 (compounded and brand-name), hormone-TRT, and DTC lab testing. The directory specifically surfaces negatives that affiliate-driven competitors typically hide (BBB F ratings, Trustpilot suspected-fraudulent-review notices, active manufacturer lawsuits).
Browse the directoryHead-to-head comparisons (20 pairs)
Per-criterion verdicts with reasoning across every possible within-category pair: compounded GLP-1, branded GLP-1, hormone-TRT, and DTC lab testing. Useful when reporting on consumer-decision angles or comparing operational practices across providers.
Browse comparisonsEditorial methodology and rubric
Six-dimension scoring rubric with public weights. Tier-based verification process. Hard lines on compensation (per-click and per-qualified-consult only, never per-prescription, never pay-to-rank). Useful if you need to characterize how the directory works.
Read the methodology
Story angles we have unusual data on
Areas where our coverage goes deeper than typical affiliate-review sites and where we may be a useful primary or secondary source:
Aequita Pharmacy / Mochi Health enforcement
Washington issued Aequita a Limited Stop Service in March 2025 and announced a July 2025 agreed order with sterile-compounding restrictions and monitoring. The state reported inspection findings creating immediate jeopardy to patient safety. We corrected earlier copy that described a separate later notice and treated whistleblower reports as state findings. Aequita is linked to Mochi in federal court records; current pharmacy assignment and order status remain unverified.
Eli Lilly v. multiple compounders (4:25-cv-03536)
April 2025 N.D. Cal. lawsuits against Henry Meds (Adonis Health), Mochi Health, Fella Health, and Willow Health over compounded-tirzepatide marketing. We link the September 2025 partial-dismissal ruling on the Henry Meds motion and the September 2026 ruling in the Mochi case. These rulings address claims at particular stages and do not establish liability or final outcomes.
Novo Nordisk v. Mochi Health (5:25-cv-06563)
Novo filed this civil case in August 2025. A September 2026 court order shows discovery proceedings, not a finding of liability. Both Novo and Lilly have alleged corporate practice of medicine in their respective cases; the theory is not unique to Novo.
Hims-Novo Nordisk dispute timeline (2025-2026)
The full chronology from April 2025 partnership announcement through June 2025 termination, twin September 9, 2025 FDA warning letters (CMS #716567 and #716825), February 2026 lawsuit, and March 9, 2026 settlement that re-established Hims as an authorized branded GLP-1 seller. Each event is linked to its primary source.
Trustpilot suspected-fraudulent-review notice methodology
Trustpilot occasionally flags business profiles with a suspected-fraudulent-review notice. We weight that flag more heavily than headline star averages. Henry Meds carries the notice on its profile despite a 4.5/5 average across 12,300+ reviews; we've documented this in the Henry Meds profile and across multiple comparison pages. Useful framing for stories about review-platform manipulation.
How to reach us
Designing Longevity is a one-person editorial operation. The fastest way to reach the editor is email at support@infinitegrowventures.com. Please include your publication, the story angle, and your deadline if applicable. Same-day response on most inquiries.
A note on attribution
When citing the regulatory timeline or any individual provider profile, please link back to the specific page rather than the homepage. Each event in the timeline has its own primary-source URL; please cite those sources directly when possible. If you're writing about a specific finding (e.g., the Aequita enforcement) we'd appreciate being credited as the source where you encountered the documented chronology, especially if it shapes your reporting.